Tivic Health Systems, Inc. ( (TIVC) ) has released its Q3 earnings. Here is a breakdown of the information Tivic Health Systems, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tivic Health Systems, Inc. is a diversified immunotherapeutics company focused on leveraging biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly in the field of immunotherapy. The company is advancing its biologics pipeline, including its lead drug candidate Entolimod for acute radiation syndrome.
In the third quarter of 2025, Tivic Health Systems reported financial results highlighting strategic transformations and advancements in its biologics pipeline. The company is progressing towards commercial readiness, with significant developments in manufacturing processes and clinical trials.
Key financial metrics for the quarter include a revenue of $146,000, a slight increase from the previous year, and a net loss of $2.6 million compared to $1.4 million in the third quarter of 2024. Tivic has successfully transferred two INDs from Statera Biopharma, enabling clinical trials for Entolimod in treating neutropenia and cancer-related conditions. Additionally, the company has completed the cell line verification necessary for cGMP manufacturing.
Tivic has also made strategic decisions to wind down its consumer health tech business, focusing resources on its clinical pipeline. This includes discontinuing ClearUP sales and launching a new corporate website to reflect its transformed mission. The company closed multiple financing tranches, raising $3.8 million in net proceeds during the quarter.
Looking ahead, Tivic Health Systems remains committed to advancing its clinical pipeline and exploring potential pathways for deploying Entolimod as a military countermeasure. With sufficient funding and no debt, the company is well-positioned to make meaningful progress in its manufacturing validation and strategic initiatives.